Clinical trials
Immunogenicity clinical trials
Below are recruiting immunogenicity clinical trials, each written for real people, not researchers. We’re tracking 146 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07779408RecruitingPhase 1/Phase 2
H5N8 flu vaccine study for healthy adults
This study tests an experimental flu vaccine designed to protect against the H5N8 bird flu virus. It is given with an ingredient that may boost the immune response. The study will check if the vaccine is safe and how well it triggers the body's defenses.
Tempe, ArizonaAges 18 years+ - NCT07769983Enrolling by invitationPhase 1
HIV vaccine study for people on effective treatment
This study tests a new vaccine designed to help your immune system fight HIV better. It is for people with HIV who are already on effective antiretroviral therapy and have a well-controlled virus. The goal is to see if the vaccine is safe and boosts your body's natural defenses.
Bern, Canton of BernAges 18 years+ - NCT07758972RecruitingPhase 1
Gonorrhea vaccine safety study
This trial tests a new vaccine designed to protect against gonorrhea, a common sexually transmitted infection. The study checks how safe the vaccine is and how well it trains the immune system to fight the bacteria.
Neu-Ulm, BavariaAges 18–50 - NCT07764237RecruitingPhase 1
mRNA vaccine for older adults to prevent RSV and hMPV
This trial tests a new mRNA vaccine designed to protect older adults against two common respiratory viruses, RSV and hMPV. It aims to see if the vaccine is safe and creates a good immune response.
Québec, QuebecAges 60 years+ - NCT07755436RecruitingPhase 1
Study of ARR-002 for advanced ovarian or endometrial cancer
This study tests an experimental drug called ARR-002 in people with advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to standard treatments. The goal is to see if it is safe and whether it shrinks tumors.
Orlando, FloridaAges 18 years+ - NCT07726147RecruitingPhase 1
Testing a new allergy shot for Japanese cedar pollen
This trial tests a new allergy shot (ITI-9001) for people with Japanese cedar pollen allergy. It aims to see if the shot is safe and can reduce allergy symptoms. The study is for people who have not tried immunotherapy before.
Tokyo, Shinjuku-kuAges 18–65 - NCT07724106RecruitingPhase 1
NeoOVSV vaccine for ovarian cancer after surgery
This trial tests a personalized vaccine made from your own tumor tissue called NeoOVSV. It is meant to train your immune system to fight any remaining cancer after surgery. The vaccine is a personal treatment because it uses your tumor's unique markers.
Chengdu, SichuanAges 18–75 - NCT07717905RecruitingPhase 1/Phase 2
Testing BBT001 for chronic hives
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
Wuhu, AnhuiAges 18–75 - NCT07710872RecruitingPhase 3
Meningitis vaccine study for infants and toddlers
This study tests an experimental vaccine to protect babies and toddlers from meningitis (a serious infection of the brain and spinal cord). It checks how well the vaccine works and how safe it is in young children.
JingxiAges 2 months–1.9 years - NCT07694557RecruitingPhase 1
Safety and immune response study of YKYY025 RSV vaccine
This study tests a new RSV vaccine called YKYY025 in healthy adults. The main goal is to see if it is safe and to measure how the immune system responds.
Anning, YunnanAges 18 years+ - NCT07688369RecruitingPhase 1
Testing a new polio vaccine in healthy adults
This trial tests a new recombinant polio vaccine (rPV) to see if it is safe and works as well as the current IPOL vaccine. It is for healthy adults who have not had polio or a polio vaccine recently.
East Melbourne, VictoriaAges 18–60 - NCT07676890RecruitingPhase 1
Study of a personalized vaccine for ovarian cancer after surgery
This trial tests a personalized vaccine made from your tumor's genetic material. It is given after surgery to help your immune system recognize and attack any remaining cancer cells, with the goal of preventing the cancer from coming back.
Chengdu, SichuanAges 18–75 - NCT07653100RecruitingPhase 3
RSV vaccine study for adults with chronic conditions
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
Visakhapatnam, Andhra PradeshAges 18 years+ - NCT06137755RecruitingPhase 1
Shingles vaccine study for healthy adults 50-65
This trial tests a new shingles vaccine in healthy adults aged 50 to 65. Shingles can cause a painful rash, and the vaccine aims to prevent it.
Seoul, Eunpyeong-guAges 50–64 - NCT07636525Recruiting
Sleep and Teen Vaccine Response Study
This study looks at how sleep affects how well a meningococcal vaccine works in 11–12 year olds. Researchers want to understand if getting good sleep helps your body respond better to vaccines.
Cincinnati, OhioAges 11–12 - NCT07614776RecruitingPhase 3
New Eye Injection Treatment for Age-Related Macular Degeneration
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
Fullerton, CaliforniaAges 50 years+ - NCT07615985RecruitingPhase 1
Safety and Blood Levels of PMG1016 in Healthy Adults
This study tests a new experimental medicine called PMG1016 to see how safe it is and how it moves through the body in healthy volunteers. You'll receive a single dose and have your blood checked and heart monitored to make sure the medicine is well-tolerated.
Brisbane, QueenslandAges 18–55 - NCT07616934RecruitingPhase 1
Safety and immune response study of VAX-A1 vaccine in healthy young adults
This study tests a new vaccine called VAX-A1 in healthy people aged 18–40 to see if it's safe and if it helps the body build protection against Group A Streptococcus (a bacteria that can cause serious infections). You'll receive two vaccine doses and have blood tests and heart monitoring over 6 months.
Adelaide, South AustraliaAges 18–40 - NCT07605520RecruitingEarly Phase 1
COVID-19 Booster Vaccine Study for Previously Vaccinated Adults
This study tests new COVID-19 booster vaccine candidates in healthy adults who previously received mRNA COVID-19 vaccines. Researchers will monitor safety and how well your immune system responds to help develop better COVID-19 protection.
CréteilAges 18–65 - NCT07593820RecruitingPhase 1
CAR-T Cell Study for Advanced HER2-Positive Cancers
This early-stage trial tests a new type of immune cell therapy called CAR-T cells, which are designed to recognize and attack cancer cells that have a protein called HER2. The cells are made from your own immune cells, trained in the laboratory, and given back to you. The study evaluates how safe the treatment is and whether it can shrink tumors.
Barcelona, CataloniaAges 18 years+ - NCT07581509RecruitingPhase 1
Comparing two immunotherapy drugs after melanoma surgery
This study compares two immunotherapy drugs to see which is better at preventing melanoma from returning after surgery. One drug is an experimental biosimilar similar to Keytruda, and the other is Keytruda itself.
Barretos, São PauloAges 18–99 - NCT07565090RecruitingPhase 1
Sudan Virus Vaccine Safety Study for Healthy Adults
This study tests a new experimental vaccine designed to protect against Sudan virus, a rare but serious disease. Researchers will check if the vaccine is safe and helps your immune system fight off the virus.
Washington D.C., District of ColumbiaAges 18–50 - NCT06715540RecruitingPhase 1
Study of a new drug for healthy male volunteers
This trial tests a new medicine called BCD-261 in healthy men to see if it is safe and how the body processes it. Participants will receive increasing doses and be monitored for about 4 months.
Saint PetersburgAges 18–45 - NCT07555392RecruitingPhase 2/Phase 3
Chikungunya Vaccine Safety and Immune Response Study
This study tests a new vaccine to protect against chikungunya virus, a disease spread by mosquitoes that causes fever and joint pain. The study measures how well your immune system responds to the vaccine and tracks any side effects.
Guwahati, AssamAges 12–65
Hear when a new Immunogenicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunogenicity?
- Yes. Clin2 currently lists 146 recruiting immunogenicity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunogenicity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunogenicity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.